We are excited to welcome the talented team at Regulus to Novartis as we continue to build on our pipeline in renal disease with high unmet medical need.” Farabursen is an investigational ...

Basel, June 25, 2025 – Novartis today announced that its previously announced tender offer (the “Offer”) by Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of ...

Job Title Sort ascending Business Location Site Date Posted; Višji strokovnjak za področje vizualne kontrole (m/ž/d) / Senior Visual Inspection Expert (m/f/d) Regulär, Full time Innovative Medicines ...

What is Novartis Managed Access? There are instances where a patient has a serious or life-threatening disease or condition, for which all currently available treatment options have been exhausted and ...

We must fundamentally reimagine the way we work and create a culture that brings out the best in our people to fulfill our purpose of reimagining medicine to improve and extend people’s lives. We ...

If you are a final year student of undergraduate or postgraduate studies in economics, business, computer and information science, social sciences, logistics, organizational sciences, electrical ...

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the ...

Novartis may provide external funding to legitimate organizations in the interest of driving its mission to improve healthcare, advance scientific/medical knowledge or support the communities where ...

The purpose of this study is to assess whether the combination of AAA617 (administered for 6 cycles at a dose of 7.4 GBq (200 mCi) +/- 10%) and ARPI improves radiographic progression-free survival ...

Ad hoc announcement pursuant to Art. 53 LR. At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus ...

The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with ...